T1	Participants 65 87	hemodialysis patients.
T2	Participants 265 415	80 stable chronic hemodialysis patients selected on the basis of their acceptable control of serum phosphorus (P) levels with aluminum hydroxide (AH).
T3	Participants 420 477	patients were dialyzed against the same calcium dialyzate
